G Protein-coupled Receptor-targeting Antibody-drug Conjugates: Current Status and Future Directions

Overview

Journal Cancer Lett

Specialty Oncology

Date 2023 Apr 26

PMID 37100113

Authors

Peyton High

Kendra S Carmon

Affiliations

Soon will be listed here.

Abstract

In recent years, antibody-drug conjugates (ADCs) have emerged as promising anti-cancer therapeutic agents with several having already received market approval for the treatment of solid tumor and hematological malignancies. As ADC technology continues to improve and the range of indications treatable by ADCs increases, the repertoire of target antigens has expanded and will undoubtedly continue to grow. G protein-coupled receptors (GPCRs) are well-characterized therapeutic targets implicated in many human pathologies, including cancer, and represent a promising emerging target of ADCs. In this review, we will discuss the past and present therapeutic targeting of GPCRs and describe ADCs as therapeutic modalities. Moreover, we will summarize the status of existing preclinical and clinical GPCR-targeted ADCs and address the potential of GPCRs as novel targets for future ADC development.

Citing Articles

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer.

Jacob J, Anami Y, High P, Liang Z, Subramanian S, Ghosh S Cancer Res. 2024; 85(5):973-986.

PMID: 39693606 PMC: 11875910. DOI: 10.1158/0008-5472.CAN-24-0798.

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer.

Jacob J, Anami Y, High P, Liang Z, Subramanian S, Ghosh S bioRxiv. 2024; .

PMID: 39605519 PMC: 11601497. DOI: 10.1101/2024.02.20.581056.

Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation.

Khetan R, Eldi P, Lokman N, Ricciardelli C, Oehler M, Blencowe A J Ovarian Res. 2024; 17(1):156.

PMID: 39068454 PMC: 11282829. DOI: 10.1186/s13048-024-01479-0.

The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.

High P, Guernsey C, Subramanian S, Jacob J, Carmon K Pharmaceutics. 2024; 16(7).

PMID: 39065587 PMC: 11279420. DOI: 10.3390/pharmaceutics16070890.

Technologies for the discovery of G protein-coupled receptor-targeting biologics.

Downey M, Peralta-Yahya P Curr Opin Biotechnol. 2024; 87:103138.

PMID: 38728825 PMC: 11250939. DOI: 10.1016/j.copbio.2024.103138.

References

Balkwill F . The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14(3):171-9. DOI: 10.1016/j.semcancer.2003.10.003. View

Park S, Wu L, Tu J, Yu W, Toh Y, Carmon K . Unlike LGR4, LGR5 potentiates Wnt-β-catenin signaling without sequestering E3 ligases. Sci Signal. 2020; 13(660). PMC: 7905944. DOI: 10.1126/scisignal.aaz4051. View

Pillow T, Adhikari P, Blake R, Chen J, Rosario G, Deshmukh G . Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity. ChemMedChem. 2019; 15(1):17-25. DOI: 10.1002/cmdc.201900497. View

Huang H, Wu T, Shi H, Wu Y, Yang H, Zhong K . Modular design of nanobody-drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent. Chem Commun (Camb). 2019; 55(35):5175-5178. DOI: 10.1039/c9cc01391a. View

Hase M, Yokomizo T, Shimizu T, Nakamura M . Characterization of an orphan G protein-coupled receptor, GPR20, that constitutively activates Gi proteins. J Biol Chem. 2008; 283(19):12747-55. DOI: 10.1074/jbc.M709487200. View

Jazayeri A, Dias J, Marshall F . From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. J Biol Chem. 2015; 290(32):19489-95. PMC: 4528114. DOI: 10.1074/jbc.R115.668251. View

Jung Y, Park J . Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020; 52(2):183-191. PMC: 7062731. DOI: 10.1038/s12276-020-0380-6. View

Wong C, Mulero M, Barth E, Wang K, Shang X, Tikle S . Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer. J Pharmacol Exp Ther. 2023; 385(2):95-105. PMC: 10108443. DOI: 10.1124/jpet.122.001495. View

Congreve M, de Graaf C, Swain N, Tate C . Impact of GPCR Structures on Drug Discovery. Cell. 2020; 181(1):81-91. DOI: 10.1016/j.cell.2020.03.003. View

10.

Moo E, van Senten J, Brauner-Osborne H, Moller T . Arrestin-Dependent and -Independent Internalization of G Protein-Coupled Receptors: Methods, Mechanisms, and Implications on Cell Signaling. Mol Pharmacol. 2021; 99(4):242-255. DOI: 10.1124/molpharm.120.000192. View

11.

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y . G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021; 6(1):7. PMC: 7790836. DOI: 10.1038/s41392-020-00435-w. View

12.

Insel P, Sriram K, Wiley S, Wilderman A, Katakia T, McCann T . GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. Front Pharmacol. 2018; 9:431. PMC: 5972277. DOI: 10.3389/fphar.2018.00431. View

13.

Gupta P, Furness S, Bittencourt L, Hare D, Wookey P . Building the case for the calcitonin receptor as a viable target for the treatment of glioblastoma. Ther Adv Med Oncol. 2021; 12:1758835920978110. PMC: 7758865. DOI: 10.1177/1758835920978110. View

14.

George S, Heinrich M, Somaiah N, Oppelt P, McLeod R, Nishioka S . A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor. Clin Cancer Res. 2023; 29(18):3659-3667. PMC: 10502450. DOI: 10.1158/1078-0432.CCR-23-0640. View

15.

Bianchi M, Mezzapelle R . The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. Front Immunol. 2020; 11:2109. PMC: 7484992. DOI: 10.3389/fimmu.2020.02109. View

16.

Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

17.

Yamazaki C, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J . Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021; 12(1):3528. PMC: 8192907. DOI: 10.1038/s41467-021-23793-7. View

18.

Orouji E, Raman A, Singh A, Sorokin A, Arslan E, Ghosh A . Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut. 2021; 71(5):938-949. PMC: 8745382. DOI: 10.1136/gutjnl-2020-322835. View

19.

Gebleux R, Stringhini M, Casanova R, Soltermann A, Neri D . Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer. 2016; 140(7):1670-1679. PMC: 5606289. DOI: 10.1002/ijc.30569. View

20.

Andreev J, Thambi N, Perez Bay A, Delfino F, Martin J, Kelly M . Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Mol Cancer Ther. 2017; 16(4):681-693. DOI: 10.1158/1535-7163.MCT-16-0658. View